Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $91.20.

Several equities research analysts have commented on HALO shares. TD Cowen boosted their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Citizens Jmp lifted their price target on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Finally, Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $83.00 to $110.00 in a research note on Friday, August 7th.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $107.24, for a total transaction of $2,144,800.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $82,336,727.20. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 5,230 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $108.54, for a total transaction of $567,664.20. Following the sale, the director directly owned 53,609 shares in the company, valued at approximately $5,818,720.86. The trade was a 8.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 85,852 shares of company stock valued at $9,158,446. Corporate insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HALO. Bank of America Corp DE acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $214,504,000. William Blair Investment Management LLC acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at approximately $196,540,000. Norges Bank acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at approximately $128,201,000. Jupiter Topco LLC purchased a new stake in Halozyme Therapeutics in the second quarter valued at approximately $105,570,000. Finally, Caisse de depot et placement du Quebec purchased a new stake in Halozyme Therapeutics in the second quarter valued at approximately $83,940,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $109.72 on Wednesday. The firm has a market cap of $12.45 billion, a PE ratio of 32.75, a P/E/G ratio of 0.41 and a beta of 0.88. Halozyme Therapeutics has a twelve month low of $61.22 and a twelve month high of $116.85. The business has a 50-day moving average price of $104.56 and a 200 day moving average price of $82.20. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The firm had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business’s revenue was up 47.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Sell-side analysts predict that Halozyme Therapeutics will post 8.25 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.